Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc.

NVCTNYSE / NASDAQHealthcareSmall cap

$19.39-$0.45 (-2.3%)

Last close · Data as of Nov 20, 2026

Market cap
$256.5M
P/E
-9.7x
Revenue
$0.00
ROCE
-149.8%

+229.8% over the last year

Nuvectis Pharma, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-5.8%
3M
-17.0%
6M
+82.4%
1Y
+229.8%
5Y
Short history
  • A period is left blank when the price history is shorter than the period.

52-week range

Day change -$0.45 (-2.3%) from $20 to $19 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in NVCT, bought on each weekday since 2022.

News & filings

What Nuvectis Pharma filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 26.4 million US dollars in fiscal 2025.

Strengths (1)

  • The price is 25.4% above its 200-day average, and the 50-day average is above the 200-day.
  • Revenue is too small for margins and growth rates to be read, so those points are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Sector
Healthcare
Shares outstanding
25.7M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$256.5M
P/E
-9.7x
P/B
13.9x
52-week high
$28.53
52-week low
$5.81

Profitability

ROE
-143.6%
ROCE
-149.8%
ROA
-83.4%

Growth

Revenue
$0.00
Net profit growth, 1Y
39.2%
Free cash flow
-$16.0M

Solvency

Current ratio
2.38
Debt / Equity
0.00
Debt / Assets
0.00
CFO / Net profit
0.61
Cash / Market cap
12.3%

Revenue and net profit

Annual revenue, with net profit as the dashed line.

Nuvectis Pharma, Inc. revenue and net profit by fiscal year
Nuvectis Pharma, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$0.00-$19.1M
FY2023$0.00-$22.3M
FY2024$0.00-$19.0M
FY2025$0.00-$26.4M

Cash flows

FY2025: -$16.0M from operations, -$16.0M free after investment (dashed).

Nuvectis Pharma, Inc. operating and free cash flow by fiscal year
Nuvectis Pharma, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$13.6M-$13.6M
FY2023-$16.0M-$16.0M
FY2024-$12.2M-$12.2M
FY2025-$16.0M-$16.0M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$0.00
EBITDA
-$27.6M
Net profit
-$26.4M
Cash from operations
-$16.0M
Free cash flow
-$16.0M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$0.00-$27.6M-$26.4M-$16.0M-143.6%—+39.2%

Monthly returns

Month-by-month returns of NVCT across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$31.7M
Non-current assets$0.00
Liabilities$13.3M
Non-current liabilities$0.00
Equity$18.4M
Paid-in capital$118.1M
Retained earnings-$99.7M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; NVCT highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

Not shown (no positive earnings and no EV / Sales): Nuvectis Pharma, Inc., Anavex Life Sciences Corp., Protara Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Nuvectis Pharma, Inc.NVCTthis company$256.5M-9.7x13.9x-143.6%—
Entrada Therapeutics, Inc.TRDA$271.7M-1.9x0.9x-47.0%-1.5x
Anavex Life Sciences Corp.AVXL$261.3M-5.6x2.8x-48.9%—
Akebia Therapeutics, Inc.AKBA$260.3M-48.7x8.0x-16.4%5.9x
Fate Therapeutics, Inc.FATE$257.6M-1.9x1.2x-65.8%-2.1x
Codexis, Inc.CDXS$254.5M-5.8x5.0x-87.0%-8.2x
Sight Sciences, Inc.SGHT$250.3M-6.5x3.9x-60.1%-6.1x
Protara Therapeutics, Inc.TARA$247.9M-4.3x1.3x-29.2%-3.1x
Coherus Oncology, Inc.CHRS$242.9M1.4x4.0x275.4%-1.1x
Peer median—-5.0x3.3x-47.9%-2.1x

Year-to-date ROI

NVCT since 1 January, against earlier years.

Historical volatility

NVCT's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

LineFY2025
Operating expensesOperating Expense$27.6M
Research and developmentResearch And Development$18.1M
Insurance and claimsInsurance And Claims$600.0k
Total expensesTotal Expenses$27.6M
Pretax incomePretax Income-$26.4M

Learn while you research

Academy chapters picked for Nuvectis Pharma, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →